

AUGUREX COMPLETES LICENSING-IN OF ITS ARTHRITIS BIOMARKER

October 11, 2007

Augurex Life Sciences Corp. is pleased to announce that it has entered into a license agreement with the University of British Columbia for the rights to develop and commercialize a technology for the diagnosis of arthritis. The agreement gives Augurex an exclusive world-wide license to the diagnostic technology, which is a co-invention between the University of Alberta and the University of British Columbia.

Currently, the only clinically approved way to detect structural damage in arthritis is through the use of imaging, such as x-rays, which require significant cost and expertise to interpret. It is planned that the Augurex blood test will provide doctors with a quantitative readout which would allow them to make an immediate clinical decision for the management of arthritis patients. The diagnosis, treatment and productivity loss related to arthritis currently costs the healthcare system \$7 billion per year in Canada and \$80 billion USD in the United States.

Dr. Anthony Marotta, Augurex's Chief Scientific Officer and co-founder, said, "Earlier and more effective methods of diagnosing and managing the disease, including the selection of appropriate drug treatments, could help increase the productivity of arthritis patients and allow them to live healthier lives which would ultimately reduce the massive economic draw of this disease on the healthcare system."

The co-inventors of the technology, Drs. Aziz Ghahary, Ruhangiz Kilani from the University of British Columbia and Dr. Walter Maksymowych from the University of Alberta are recognized leaders in their fields and Augurex looks forward to working closely with them to maximize the utility of the blood test so that arthritis patients may benefit from their innovative discovery.

It is estimated that 124 million people worldwide suffer from different forms of arthritis, and earn on average 10% less income than healthy individuals. Fifty percent (50%) of patients with a specific form of arthritis, called rheumatoid arthritis, cannot work within 10 years of their diagnosis due to the debilitating nature of the disease.

According to Norma Biln, Augurex's Chief Executive Officer and co-founder, "We believe that the arthritis blood test that Augurex is developing has the potential to provide a positive impact on the quality of life for arthritis patients since earlier detection coupled with the appropriate treatment could slow down the irreversible progression of the disease."

About Biomarkers

Biomarkers can be measured in the blood to indicate to doctors what might be going on in the body. This helps them make a proper diagnosis and make decisions regarding the speed at which the disease is progressing, the appropriate drugs to prescribe or whether further diagnostic testing is required. Biomarkers are playing an increasingly important role in today's healthcare

environment with a significant focus on early disease detection, personalized medicine and the use of markers in pharmaceutical clinical studies to measure the effectiveness of drugs and their side effects. Food and drug regulators are putting an emphasis on the use of biomarkers, as was outlined in the Critical Path Opportunities Report put out by the FDA in March of 2006.

http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf

About Augurex

Augurex Life Sciences Corp. is focused on the identification of early-stage biomarkers and develops them in an efficient way as to ensure that innovative products, like the arthritis blood test, are made readily accessible to patients around the world. Augurex uses its expertise in *in-vitro*, protein-based product development to unlock the commercial potential of promising patent-protected technologies. For more information on Augurex please visit: www.augurex.com

For further information please contact:

Norma K. Biln, BSc, MBA

CEO and Co-founder

Augurex Life Sciences Corporation

Tel: 778-839-3319

nbiln@augurex.com